Brooklyn Boro

Brooklyn Army Terminal-based company seeks to market bleeding-control gel to humans

Already used for animals, was invented by then-NYU freshman

December 3, 2021 Brooklyn Eagle Staff
Share this:

A Brooklyn-based biotech company has applied for FDA approval for the human use of a plant-based gel technology that the company says rapidly controls bleeding and seals wounds in less than 10 seconds.

The company is Cresilon, and the hemostatic gel is known as VETIGEL. It was created by Brooklynite Joe Landolina when he was a 17-year-old freshman at NYU, 11 years ago.

A review published in the New England Journal of Medicine says over 2 million people who die from hemorrhaging each year. The gel, which is currently used to treat bleeds within the animal and pet community, could transform the future of trauma and abrasion care for humans and advance the company’s mission to save lives.

Landolina manufactures his revolutionary gel at his 25,000-square-foot facility at Industry City in Brooklyn. By the end of next year, Cresilon plans to double its local workforce, which is currently a team of 50 employees, according to the company.

News for those who live, work and play in Brooklyn and beyond

The company raised $38.5 million in funding last year, according to a company statement. The creation of the gel made Landolina a TED fellow.

Brooklyn inventor and entrepreneur Joe Landolina. Facebook photo

“This FDA submission marks an important milestone for Cresilon in our commitment to significantly improve the standard of care in wound treatment,” said Landolina, CEO of Cresilon. “Cresilon’s mission is to save lives, and we are eager for our technology to be permitted to make a significant positive impact in the human health market, just as we are already doing in the animal health market.”

The polymers that make up VETIGEL, which is being marketed under the name of Traumagel, are taken from the cell walls of algae, which is similar to the material that makes up human tissue, according to a video produced by the company.

“We see a significant opportunity for our technology in the human market, and this FDA submission is Cresilon’s first step towards seizing that opportunity,” he added. “We look forward to working through the FDA review process to obtain clearance for Cresilon Hemostatic Gel.”

Leave a Comment

Leave a Comment